GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Mezzion Pharma Co 140410.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

65,700

+4.95%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩7.91bn

FY2016FY2025

Net income

−₩34.93bn

FY2016FY2025

Free cash flow

−₩29.86bn

FY2016FY2025

Shareholders' equity

₩17.19bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩7.91bn₩8.61bn₩31.72bn₩30.73bn₩26.65bn₩28.63bn₩18.93bn₩19.09bn₩5.59bn₩8.75bn
Gross profit₩1.45bn₩1.91bn₩3.88bn−₩313.4m₩3.70bn₩7.44bn₩3.10bn₩3.24bn₩898.6m₩4.96bn
Research and development₩1.26bn₩294.0m₩939.0m₩2.22bn₩1.96bn₩937.6m—₩11.55bn₩11.09bn₩7.00bn
Operating income—−₩14.30bn−₩14.34bn−₩23.33bn−₩16.80bn−₩7.53bn−₩24.66bn−₩21.93bn−₩16.89bn−₩7.64bn
Net income−₩34.93bn−₩19.48bn−₩12.73bn−₩36.30bn−₩13.60bn−₩13.83bn−₩23.25bn−₩18.88bn−₩14.88bn−₩12.98bn
Diluted earnings per share-1,149.27-650.02-431.34-1,357.33-509.40-529.14-2,670.74-2,212.00-1,981.91-587.28

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩98.02bn₩74.00bn₩92.15bn₩54.02bn₩83.93bn₩75.63bn₩58.87bn₩75.06bn₩74.04bn₩95.90bn
Cash and short-term investments—₩28.62bn₩58.25bn₩32.40bn₩47.21bn₩49.10bn₩41.16bn₩55.07bn₩61.76bn₩89.06bn
Total liabilities₩80.83bn₩27.94bn₩30.70bn₩27.78bn₩21.14bn₩18.82bn₩16.04bn₩17.74bn₩20.87bn₩43.09bn
Debt—₩1.62bn₩2.24bn₩3.71bn₩4.32bn₩5.10bn₩3.60bn₩239.0m₩8.18bn₩26.25bn
Shareholders' equity₩17.19bn₩46.06bn₩61.44bn₩26.24bn₩62.79bn₩56.81bn₩42.83bn₩57.32bn₩53.17bn₩52.81bn
Shares outstanding30m30m30m27m27m26m9m9m8m22m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−₩16.59bn−₩18.49bn−₩11.02bn−₩12.07bn−₩15.07bn−₩7.38bn−₩20.88bn−₩21.72bn−₩13.21bn−₩6.08bn
Capital spending−₩13.27bn−₩13.48bn−₩11.86bn−₩1.76bn−₩357.8m−₩774.2m−₩1.10bn−₩572.1m−₩719.9m−₩169.0m
Free cash flow−₩29.86bn−₩31.97bn−₩22.88bn−₩13.84bn−₩15.43bn−₩8.15bn−₩21.98bn−₩22.30bn−₩13.93bn−₩6.25bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩2.20bn₩2.02bn₩2.08bn₩2.13bn₩1.74bn₩1.95bn₩1.92bn₩2.26bn
Gross profit₩402.9m₩349.3m₩369.2m₩392.6m₩340.2m₩350.2m₩422.9m₩513.9m
Operating income—−₩4.62bn−₩5.05bn−₩4.68bn₩340.2m−₩3.52bn−₩3.98bn−₩1.66bn
Net income₩7.69bn−₩5.31bn−₩24.64bn−₩5.13bn−₩1.85bn−₩3.31bn−₩11.60bn−₩6.33bn
Diluted earnings per share252.87-174.63-810.75-169.72-61.66-110.26-387.09-211.38
Cash from operations−₩4.75bn−₩6.07bn−₩6.84bn−₩2.83bn−₩3.22bn−₩3.70bn−₩18.49bn−₩17.12bn
Capital spending−₩3.81bn−₩2.87bn—−₩5.67bn−₩4.59bn−₩4.21bn−₩13.48bn−₩8.14bn
Free cash flow−₩8.56bn−₩8.94bn—−₩8.49bn−₩7.80bn−₩7.92bn−₩31.97bn−₩25.25bn
Total assets₩125.25bn₩98.92bn₩98.02bn₩87.88bn₩89.11bn₩70.84bn₩74.00bn₩74.24bn
Cash and short-term investments—————₩21.08bn₩28.62bn₩34.73bn
Debt—————₩884.9m₩921.5m₩812.1m
Shareholders' equity₩39.04bn₩15.51bn₩17.19bn₩37.35bn₩41.18bn₩43.26bn₩46.06bn₩53.76bn

Financial ratios

Data as of 26 Aug 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Gross margin18.4%22.2%12.2%-1.0%13.9%26.0%——
Operating margin—-166.0%-45.2%-75.9%-63.0%-26.3%-129.3%—
Net margin-441.6%-226.2%-40.1%-118.1%-51.0%-48.3%——
Return on equity-203.1%-42.3%-20.7%-138.3%-21.7%-24.3%——
Return on assets-35.6%-26.3%-13.8%-67.2%-16.2%-18.3%——
Free cash flow yield——0.0%-0.6%-0.8%-0.4%-3.4%-3.7%
Revenue growth-8.2%-72.9%3.2%15.3%-6.9%51.3%——
Earnings growth79.3%53.0%-64.9%166.8%-1.6%-40.5%——
Current ratio0.57x1.57x2.51x1.76x3.47x3.91x——
Debt to equity—0.00x0.01x0.04x0.01x0.02x0.01x—
Equity ratio17.5%62.2%66.7%48.6%74.8%75.1%——
Interest coverage—-47.54x-45.45x-55.10x-51.94x-23.52x——
R&D as a share of sales15.9%3.4%3.0%7.2%7.3%3.3%——
Buybacks as a share of market value——-10.3%-0.1%-2.2%-200.2%-2.0%-13.6%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-36.4%-22.7%-6.2%
Net income-1.3%20.4%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin20.4%8.8%13.5%19.9%
Net margin-329.3%-131.0%-97.5%-97.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-78.4-47.5-90.4-9.6-81.2-63.3-13.6-7.9-3.8-7.5
Price to sales346.2107.336.311.341.430.616.87.810.211.1

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 27 Dec 2012.

FY2012
Paid in the year8.333
  • 959692-for-319897 split · 5 Apr 2022

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.